Fouad Moawad, MD
Internal Medicine · la Jolla, CANPI 1447221007
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $571,363 of the $725,249 with a category attached, or 78.8%. 28 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 42.3% of the total. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 759 payments — averaging $955.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$307K
- Sanofi$267K
- Sanofi-aventis U.S. LLC$93K
- Takeda Pharmaceuticals U.S.A., Inc.$32K
- Phathom Pharmaceuticals, Inc.$13K
- Regeneron$5K
- plus $8K from 22 others
Across 65 payments — averaging $2309.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$150K
What the payments were for
- Consulting fees$31,0764%
- Speaking & faculty fees$571,36379%
- Travel & lodging$106,65715%
- Food & beverage$15,9682%
- Education$1850%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 266 | $307,075 |
| Sanofi | 185 | $266,908 |
| Sanofi-aventis U.S. LLC | 12 | $93,358 |
| Takeda Pharmaceuticals U.S.A., Inc. | 65 | $31,720 |
| Phathom Pharmaceuticals, Inc. | 28 | $13,174 |
| Regeneron | 8 | $5,310 |
| AbbVie(2 entities) | 80 | $2,666 |
| AstraZeneca | 2 | $2,264 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 33 | $1,215 |
| Johnson & Johnson | 15 | $387 |
| Merck | 15 | $274 |
| Ferring Pharmaceuticals Inc. | 13 | $214 |
| QOL Medical, LLC | 7 | $115 |
| Aimmune Therapeutics, Inc. | 4 | $108 |
| Redhill Biopharma Inc. | 3 | $76 |
| Ardelyx, Inc. | 3 | $64 |
| Bristol Myers Squibb | 4 | $62 |
| Braintree Laboratories, Inc. | 3 | $49 |
| Celltrion USA Inc. | 2 | $34 |
| Pfizer | 2 | $30 |
| Phadia US Inc. | 2 | $27 |
| Novo Nordisk | 1 | $23 |
| Shire North American Group Inc | 1 | $21 |
| Laborie Medical Technologies Corp. | 1 | $18 |
| Pinnacle Biologics, Inc | 1 | $16 |
| W. L. Gore & Associates, Inc. | 1 | $15 |
| Intercept Pharmaceuticals, Inc. | 1 | $15 |
| Vivus LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$725,249 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 11 | $79,720 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 196 | $13,049 |
| LinzessLinaclotide | 13 | $12,194 |
| Dexlansoprazole DrDexlansoprazole | 22 | $5,848 |
| Omeprazole | 93 | $1,786 |
| Pantoprazole Sodium | 87 | $1,601 |
| Esomeprazole Magnesium | 22 | $664 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 18 | $241 |
| Famotidine | 16 | $185 |
| Lactulose | 12 | $10 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $2,666 | $12,19413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.
Other internal medicine in la Jolla
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Lewis Rubinla Jolla$265K
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Fred CohenSan Francisco$929K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.